Complete picture of genetic errors can advance precision medicine approaches to treatment
A new test for two blood cancers — developed by a team at Washington University School of Medicine in St. Louis — is the first whole-genome sequencing test for cancer to be approved for reimbursement by the Centers for Medicare & Medicaid Services. The test, known as ChromoSeq, advances precision medicine approaches for treating blood cancers by identifying the full suite of genetic changes in a patient’s cancer cells, which provides crucial information that physicians can use to help determine the optimal treatment strategy for individual patients.